Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - sorafenibum - compresse rivestite con film - sorafenibum 200 mg per sorafenibi tosilas, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme, hypromellosum, magnesio stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (rosso), per compresso haze corrisp. sodio 0.275 mg. - carcinoma epatocellulare, carcinoma a cellule renali, schilddrüsenkarzinom - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

medac pharma srl - sorafenib - sorafenib

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - sorafenibum - compresse rivestite con film - sorafenibum 200 mg ut sorafenibi tosilas 274 mg, hypromellosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogola, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 1.75 mg. - carcinoma epatocellulare, carcinoma a cellule renali, schilddrüsenkarzinom - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - carcinoma, cellule renali - inibitori della proteina chinasi - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - sorafenib - carcinoma, hepatocellular; carcinoma, renal cell - agenti antineoplastici - epatocellulare carcinomanexavar è indicato per il trattamento del carcinoma epatocellulare. renale carcinomanexavar è indicato per il trattamento di pazienti con carcinoma renale avanzato, che hanno fallito prima di interferone alfa o interleuchina-2 la terapia a base di o che sono considerati non idonei per tale terapia. differenziato della tiroide carcinomanexavar è indicato per il trattamento di pazienti con progressiva, localmente avanzato o metastatico, differenziati (papillare/follicolare/hürthle cell) carcinoma della tiroide, refrattario a iodio radioattivo.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenti antineoplastici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - sunitinibum - capsule rigide - sunitinibum 12.5 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.47 mg. - trattamento gastrointestinale tumori stromali possono, trattamento del tumore del rene, il trattamento di neuroendokrinem carcinoma pancreatico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - sunitinibum - capsule rigide - sunitinibum 25 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, e 172 (flavum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.36 mg. - trattamento gastrointestinale tumori stromali possono, trattamento del tumore del rene, il trattamento di neuroendokrinem carcinoma pancreatico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - sunitinibum - capsule rigide - sunitinibum 50 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, e 172 (flavum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.71 mg. - trattamento gastrointestinale tumori stromali possono, trattamento del tumore del rene, il trattamento di neuroendokrinem carcinoma pancreatico - synthetika